Investors Bet Big on Dermatology
$100 million investment drives next-gen treatments for chronic skin conditions
Ric Edelman: It's Tuesday, April 16th. On today's show, skin problems. How's your skin? If you're like a lot of people, you have issues. And when I say a lot of people, I mean a lot of people. 25% of us have a skin condition. I'm one of them with psoriasis. With so many people dealing with so many skin issues, it's not just a huge health issue. It's big business.
Psoriasis drugs generate $13 billion in sales every year. Well, at least I have a popular disease. Drugs for atopic dermatitis, that's eczema, they do $11.5 billion in sales every year. So, as you can imagine, with sales numbers like these, Wall Street loves dermatology. Investors just gave a new biotech company $100 million in financing. They plan to use innovations in immunology to turn dermatology from a low margin business into a fast growing, high profit market. Already, there are 14 new drugs in the pipeline. Their targets include psoriasis, eczema, pruritus – that's itching, and vitiligo – the loss of skin color.
Here's what's really interesting. These new biotech firms say they're not trying to introduce drugs that do what the current drugs already do. Instead, they're creating new drugs to serve people who are currently not being served. As a result, they expect to grow the size of the market, serving more patients. And in the process, creating entirely new markets for entirely new products.
Along the way, they hope to double or triple the number of people being helped, and their profits will be astronomical. One technology being developed is short interfering RNA, which shuts down the genes responsible for inflammation of the skin. Some scientists are working with antibodies, peptides, and small molecules, and some of the drugs they're working on will be injected into the skin or injected under the skin. Others will be applied as a topical gel.
A huge area of research is to suppress itching. This is not only maddening for those who suffer from it, but worse – when you have an itch, you end up scratching. That makes the problem even worse. So they're investigating the biology of itching, so they can figure out how to stop it. Watch for the results pretty soon. Ten drugs are already in clinical trials right now. We're going to have the results within the next three years. I love it. Give people the opportunity to make a lot of money. It's amazing what solutions they'll come up with, and that helps us all.
On tomorrow's show, do we actually have a proposal for solving the social security crisis on the table?
-----
Subscribe to podcast updates: https://form.jotform.com/223614751580152
Ask Ric: https://www.thetayf.com/pages/ask-ric
-----
Follow Ric on social media:
Facebook: https://www.facebook.com/RicEdelman
Instagram: https://www.instagram.com/ric_edelman/
LinkedIn: https://www.linkedin.com/in/ricedelman/
X: https://twitter.com/ricedelman
YouTube: https://www.youtube.com/@RicEdelman
-----
Brought to you by:
Invesco QQQ: https://www.invesco.com/qqq-etf/en/home.html
Schwab: https://www.schwab.com/
Disclosure page: https://www.thetayf.com/pages/sponsorship-disclosure-fee
-----